Imugene (IMU.AX) Stock Price
Imugene Price
Revenue has compounded at 14.8% per year over the past 12 years to 1.94 M AUD. Imugene's net margin stands at -203.3%, up from -392.6% several years earlier.
Imugene stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Imugene over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Imugene stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Imugene's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Imugene Price |
|---|
Imugene Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Imugene Income Statement, Balance Sheet, Cash Flow Statement
| REVENUE (B AUD) |
|---|
| REVENUE GROWTH (%) |
| GROSS MARGIN (%) |
| GROSS INCOME (B AUD) |
| NET INCOME (M AUD) |
| NET INCOME GROWTH (%) |
| SHARES (M) |
| DOCUMENTS |
| 2023 | 2024 | 2025 | 2026e | 2027e | 2028e | 2029e | 2030e |
|---|---|---|---|---|---|---|---|
| 0 | 0 | 0 | 0.01 | 0.01 | 0.05 | 1.03 | 1.32 |
| – | – | – | – | – | 860 | 2,054.17 | 28.05 |
| – | – | – | 100 | 100 | 100 | 100 | 100 |
| 0 | 0 | 0 | 0.01 | 0.01 | 0.05 | 1.03 | 1.32 |
| -37 | -149 | -69 | -39 | -29 | -10 | 11 | 14 |
| – | 302.7 | -53.69 | -43.48 | -25.64 | -65.52 | -210 | 27.27 |
| 184.57 | 208.48 | 218.7 | 218.7 | 218.7 | 218.7 | 218.7 | 218.7 |
| – | – | – | – | – | – | – | – |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Imugene generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Imugene retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Imugene's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Imugene has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Imugene's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Imugene stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Imugene Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Imugene business model & stock analysis
Imugene SWOT Analysis
Strengths
Imugene Ltd has a strong portfolio of innovative biotechnology products, providing them with a competitive advantage in the market. Their products have shown promising results in the treatment of various diseases, positioning the company as a leader in the industry.
Weaknesses
One of the weaknesses of Imugene Ltd is its heavy reliance on external funding for research and development. This raises concerns about the company's financial stability and ability to sustain long-term growth. Additionally, Imugene Ltd may lack the resources and infrastructure compared to larger competitors.
Opportunities
There are several opportunities for Imugene Ltd to capitalize on. The increasing demand for effective biotechnology solutions presents a significant market potential for the company. Moreover, strategic partnerships and collaborations with established pharmaceutical companies can provide access to additional resources and expand Imugene Ltd's market presence.
Threats
Imugene Ltd faces several threats that could impact its operations. Regulatory hurdles and compliance requirements in the biotechnology industry present challenges that may delay product approvals and market entry. Furthermore, intense competition from other biotechnology companies with similar products and technologies can erode Imugene Ltd's market share.
Imugene Eulerpool Fair Value
Imugene historical P/E ratio, EBIT multiple, and P/S ratio
Imugene annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Imugene shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Imugene Earnings Estimates
| Date | EPS estimate | Revenue Estimate | Quarterly report |
|---|---|---|---|
| 2/27/2024 | 0AUD | 0AUD | 2024 Q2 |
| 8/28/2023 | 0AUD | 0AUD | 2023 Q4 |
| 2/26/2023 | 0AUD | 0AUD | 2023 Q2 |
| 7/25/2022 | -0AUD | 0AUD | 2022 Q4 |
| 2/28/2022 | -0AUD | -AUD | 2022 Q2 |
| 8/30/2021 | -0AUD | 0AUD | 2021 Q4 |
| 2/26/2021 | -0AUD | 0AUD | 2021 Q2 |
EESG©
Eulerpool ESG Scorecard© for the Imugene stock
EEnvironment
20
Environment
SSocial
20
Social
GGovernance (Corporate Governance)
4
Governance (Corporate Governance)
The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.
Imugene shareholder structure
| % | Name |
|---|---|
5.52644% | |
3.57162% | |
2.54107% | |
1.58689% | |
1.29833% | |
1.14967% |
Imugene Executives and Management Board
Ms. Leslie Chong
Chief Executive Officer, Managing Director, Executive Director · since 2015
Dr. Paul Woodard
Chief Medical Officer
Dr. Bradley Glover
(55)Chief Operating Officer
Dr. Monil Shah
Chief Business Officer
Mr. Paul Hopper
(66)Executive Chairman of the Board · since 2012
Imugene Supply Chain
Frequently asked questions about Imugene
Imugene Ltd is a biotechnology company specializing in the development and commercialization of innovative immunotherapies for the treatment of various cancers. Their business model revolves around leveraging cutting-edge technologies and scientific expertise to create targeted and personalized immunotherapies that activate the body's own immune system to fight cancer. Imugene aims to improve patient outcomes and address the unmet medical needs in oncology by advancing their immunotherapy pipeline. With a focus on developing novel treatments and strategic partnerships, Imugene is dedicated to making a significant impact in the field of cancer immunotherapies.
Imugene stock
Imugene Peer Group
Imugene Ticker
Imugene FIGI
All fundamentals and in-depth analysis of Imugene
Our stock analysis for Imugene stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Imugene. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.